rediff.com
REAL-TIME QUOTE
Enter Company or MF
e.g. Tata motors, Reliance MF, 500570
Sanofi India Ltd - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure) Regulations (LODR) And Company'S Policy Of Determination Of Materiality Of Events Under Regulation 30 Of LODR
Download announcement < Back
16 Sep 2022
The Ministry of Health and Family Welfare, Government of India, has released the revised National List of Essential Medicines (NLEM), 2022. In the coming days, the National Pharmaceutical Pricing Authority will fix the ceiling price for the cost to patients of the products included in this revised list. Since insulin glargine (100 IU/ ml) is now a part of the NLEM 2022 list, our Company&apos;s insulin glargine brand Lantus?? will also be subject to price revision. The potential impact on the Company will be known only after the NPPA releases the prices. Though the price revision is likely to have an impact on sales, the Company does not expect a material impact on the profitability considering the arms-length operating model principle being followed with regard to sourcing of this product from Sanofi Group.
View all announcements for Sanofi India Ltd Source: BSE India

Mutual Fund Selector

Find the fund that is right for you

Buy? Sell? Hold?

Get the Latest Stock Tips